Baxter International Inc vs VanEck Australian Floating Rate ETF — how do they compare? Baxter International Inc trades at $26.85 (market cap $14.27B), while VanEck Australian Floating Rate ETF trades at $50.93. The key difference: Baxter International Inc pays a 0.14% dividend while VanEck Australian Floating Rate ETF pays none, and Baxter International Inc is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.
| BAX | FLOT | |
|---|---|---|
Market Cap | $14.27B | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.35 | $51.09 |
52-Week Low | $15.80 | $50.72 |
Enterprise Value | $21.79B | — |
Dividend Yield | 0.14% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International Inc. (BAX) trades at $27.78, up 0.83% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.56 versus $0.37 expected, and revenue guidance was raised, signaling operational improvement. However, the company posted a net loss of -$957 million in 2025, with negative profit margins and high P/E of 87.85, reflecting valuation concerns amid turnaround efforts.
The stock shows potential from earnings momentum and cost initiatives, but high debt and inconsistent profitability pose risks. Analyst consensus is mixed with a $25.43 price target below current levels, suggesting cautious optimism. Investors should weigh recent beats against structural challenges in the medtech sector.
FLOT trades at $50.925 with minimal daily movement (+0.01%). Technical indicators show a bearish trend with all 13 moving averages signaling sell. The ETF maintains consistent dividend payments with recent distributions of $0.17-$0.18. Market focus remains on Federal Reserve policy as floating rate bonds like FLOT could benefit from potential rate hikes later in 2026.
FLOT offers exposure to high-quality floating rate bonds with a 4.0% SEC yield, positioned as a cash alternative with slightly higher returns than T-bills. The primary catalyst is potential Fed rate hikes, though the bearish technical picture and inflation uncertainty present near-term headwinds for price appreciation.
Trailing returns across standard periods
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →